Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Disaster Planning | 5 | 2018 | 549 | 1.270 |
Why?
|
Quality of Life | 37 | 2018 | 12730 | 0.880 |
Why?
|
Information Dissemination | 2 | 2021 | 1100 | 0.790 |
Why?
|
Civil Defense | 3 | 2018 | 109 | 0.730 |
Why?
|
Hospitalization | 8 | 2019 | 10232 | 0.690 |
Why?
|
Public Health Administration | 3 | 2018 | 239 | 0.680 |
Why?
|
Hypoglycemic Agents | 8 | 2020 | 2866 | 0.670 |
Why?
|
Demyelinating Diseases | 1 | 2019 | 363 | 0.570 |
Why?
|
Medication Reconciliation | 1 | 2018 | 151 | 0.560 |
Why?
|
Vaccines | 2 | 2022 | 817 | 0.560 |
Why?
|
Child, Hospitalized | 1 | 2017 | 174 | 0.540 |
Why?
|
Jaundice, Neonatal | 2 | 2004 | 71 | 0.480 |
Why?
|
Arthritis, Infectious | 1 | 2017 | 367 | 0.460 |
Why?
|
Osteomyelitis | 1 | 2017 | 402 | 0.460 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2016 | 277 | 0.450 |
Why?
|
Psychometrics | 6 | 2018 | 2999 | 0.440 |
Why?
|
Insulin, Long-Acting | 1 | 2012 | 57 | 0.430 |
Why?
|
Food Hypersensitivity | 1 | 2019 | 622 | 0.430 |
Why?
|
Anaphylaxis | 1 | 2019 | 746 | 0.420 |
Why?
|
Legislation, Medical | 1 | 2012 | 100 | 0.420 |
Why?
|
Public Health Practice | 1 | 2014 | 217 | 0.410 |
Why?
|
Emergencies | 1 | 2018 | 1164 | 0.400 |
Why?
|
Bacteremia | 1 | 2017 | 962 | 0.380 |
Why?
|
Ambulatory Care | 3 | 2018 | 2706 | 0.380 |
Why?
|
Models, Theoretical | 4 | 2014 | 3584 | 0.370 |
Why?
|
Nifedipine | 3 | 1998 | 226 | 0.360 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 959 | 0.360 |
Why?
|
Hypolipidemic Agents | 3 | 2003 | 604 | 0.350 |
Why?
|
Benchmarking | 3 | 2004 | 1038 | 0.340 |
Why?
|
Public Health | 2 | 2021 | 2594 | 0.340 |
Why?
|
Glipizide | 2 | 1998 | 47 | 0.330 |
Why?
|
Patient Compliance | 7 | 2013 | 2680 | 0.320 |
Why?
|
Sarcoma, Kaposi | 5 | 2002 | 370 | 0.320 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2012 | 3336 | 0.310 |
Why?
|
Stress, Psychological | 5 | 2012 | 4229 | 0.300 |
Why?
|
Hypertension | 15 | 2013 | 8455 | 0.290 |
Why?
|
United States | 23 | 2021 | 69693 | 0.280 |
Why?
|
Health Services Research | 4 | 2000 | 1834 | 0.280 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2020 | 11695 | 0.270 |
Why?
|
Antihypertensive Agents | 9 | 2013 | 2043 | 0.270 |
Why?
|
Diabetes Mellitus | 4 | 2019 | 5724 | 0.250 |
Why?
|
Cross-Sectional Studies | 13 | 2021 | 24913 | 0.250 |
Why?
|
Phototherapy | 2 | 2004 | 377 | 0.240 |
Why?
|
HIV Infections | 12 | 2014 | 16678 | 0.240 |
Why?
|
Male | 77 | 2021 | 349538 | 0.240 |
Why?
|
Adolescent | 27 | 2020 | 85649 | 0.240 |
Why?
|
Child, Preschool | 11 | 2019 | 40955 | 0.230 |
Why?
|
Hyperbilirubinemia | 1 | 2003 | 77 | 0.230 |
Why?
|
Humans | 121 | 2023 | 742088 | 0.230 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2005 | 2231 | 0.230 |
Why?
|
Hypoglycemia | 3 | 2020 | 859 | 0.230 |
Why?
|
Blood Glucose | 9 | 2020 | 6249 | 0.220 |
Why?
|
Hematologic Neoplasms | 3 | 2023 | 1820 | 0.220 |
Why?
|
Infant, Newborn | 12 | 2019 | 25575 | 0.220 |
Why?
|
Patient Satisfaction | 4 | 2013 | 3391 | 0.220 |
Why?
|
Hyperlipidemias | 3 | 2003 | 786 | 0.220 |
Why?
|
Athletic Injuries | 1 | 2012 | 1153 | 0.210 |
Why?
|
Female | 66 | 2021 | 379592 | 0.210 |
Why?
|
Didanosine | 1 | 2002 | 153 | 0.210 |
Why?
|
Insulin | 5 | 2015 | 6575 | 0.210 |
Why?
|
Atenolol | 2 | 1993 | 100 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 3 | 2021 | 3014 | 0.200 |
Why?
|
Asthma | 2 | 2019 | 5955 | 0.200 |
Why?
|
Caregivers | 2 | 2023 | 2074 | 0.200 |
Why?
|
Brain Concussion | 1 | 2012 | 1318 | 0.200 |
Why?
|
Hate | 1 | 2020 | 10 | 0.190 |
Why?
|
Zidovudine | 2 | 1994 | 620 | 0.190 |
Why?
|
Communications Media | 1 | 2021 | 43 | 0.190 |
Why?
|
Amlodipine | 2 | 2013 | 83 | 0.190 |
Why?
|
Risk Assessment | 5 | 2017 | 23320 | 0.190 |
Why?
|
Sex Distribution | 2 | 2017 | 2295 | 0.180 |
Why?
|
Onychomycosis | 1 | 2000 | 47 | 0.180 |
Why?
|
CD4 Lymphocyte Count | 5 | 2012 | 2557 | 0.180 |
Why?
|
Child | 14 | 2019 | 77478 | 0.180 |
Why?
|
Age Distribution | 2 | 2017 | 2900 | 0.170 |
Why?
|
Adult | 55 | 2021 | 213712 | 0.170 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2018 | 357 | 0.170 |
Why?
|
HIV Wasting Syndrome | 1 | 1999 | 97 | 0.160 |
Why?
|
Cyclohexanols | 1 | 1999 | 127 | 0.160 |
Why?
|
Captopril | 4 | 1993 | 272 | 0.160 |
Why?
|
Young Adult | 13 | 2020 | 56350 | 0.160 |
Why?
|
Double-Blind Method | 16 | 2020 | 12017 | 0.160 |
Why?
|
Infant | 7 | 2019 | 35070 | 0.160 |
Why?
|
Interferon-alpha | 1 | 2002 | 895 | 0.150 |
Why?
|
Telephone | 2 | 2013 | 617 | 0.150 |
Why?
|
Communication | 2 | 2021 | 3728 | 0.150 |
Why?
|
Aged | 43 | 2023 | 162944 | 0.150 |
Why?
|
Efficiency | 1 | 2000 | 462 | 0.150 |
Why?
|
Diabetes Complications | 3 | 2019 | 1359 | 0.150 |
Why?
|
Anti-HIV Agents | 4 | 2013 | 4250 | 0.150 |
Why?
|
Middle Aged | 50 | 2020 | 213127 | 0.150 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2018 | 187 | 0.150 |
Why?
|
Respiration, Artificial | 2 | 2019 | 2566 | 0.140 |
Why?
|
Geriatric Assessment | 2 | 2022 | 1369 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2021 | 3915 | 0.140 |
Why?
|
Crime Victims | 1 | 2020 | 322 | 0.140 |
Why?
|
Socioeconomic Factors | 4 | 2016 | 7770 | 0.140 |
Why?
|
Breast Feeding | 1 | 2004 | 1339 | 0.140 |
Why?
|
Proctocolectomy, Restorative | 1 | 2018 | 189 | 0.130 |
Why?
|
Glucagon-Like Peptides | 1 | 2016 | 124 | 0.130 |
Why?
|
Risk Factors | 10 | 2019 | 72145 | 0.130 |
Why?
|
Insulin Infusion Systems | 3 | 1985 | 212 | 0.130 |
Why?
|
Calcium Channel Blockers | 1 | 1998 | 689 | 0.130 |
Why?
|
Sulfonylurea Compounds | 2 | 2020 | 204 | 0.120 |
Why?
|
Diabetic Retinopathy | 4 | 1988 | 1205 | 0.120 |
Why?
|
Primary Health Care | 4 | 2019 | 4551 | 0.120 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 279 | 0.120 |
Why?
|
Databases, Factual | 3 | 2019 | 7716 | 0.120 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 237 | 0.120 |
Why?
|
Erectile Dysfunction | 1 | 2018 | 459 | 0.120 |
Why?
|
Obesity | 1 | 2016 | 12705 | 0.120 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 1993 | 29 | 0.120 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2013 | 57 | 0.110 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2018 | 2410 | 0.110 |
Why?
|
Epidemics | 1 | 2019 | 521 | 0.110 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2018 | 6030 | 0.110 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2013 | 98 | 0.110 |
Why?
|
Musculoskeletal Diseases | 1 | 2019 | 581 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 829 | 0.110 |
Why?
|
Syndrome | 1 | 2019 | 3248 | 0.110 |
Why?
|
Practice Guidelines as Topic | 3 | 2004 | 7276 | 0.110 |
Why?
|
Immunoglobulin A | 1 | 2016 | 992 | 0.110 |
Why?
|
Louisiana | 1 | 2012 | 109 | 0.110 |
Why?
|
Vasculitis | 2 | 2016 | 521 | 0.110 |
Why?
|
History, 21st Century | 1 | 2018 | 1533 | 0.110 |
Why?
|
Vaccination | 2 | 2022 | 3256 | 0.110 |
Why?
|
Renal Artery Obstruction | 1 | 2013 | 248 | 0.100 |
Why?
|
Barbering | 1 | 2011 | 9 | 0.100 |
Why?
|
Economics, Pharmaceutical | 1 | 1992 | 87 | 0.100 |
Why?
|
Injections, Subcutaneous | 4 | 2007 | 664 | 0.100 |
Why?
|
Absenteeism | 2 | 1998 | 250 | 0.100 |
Why?
|
Retrospective Studies | 13 | 2019 | 77098 | 0.100 |
Why?
|
Random Allocation | 9 | 2017 | 2425 | 0.100 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 546 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 1999 | 1423 | 0.100 |
Why?
|
Auditory Fatigue | 1 | 2010 | 9 | 0.100 |
Why?
|
Counseling | 1 | 2019 | 1521 | 0.100 |
Why?
|
Urinary Incontinence | 1 | 1996 | 494 | 0.100 |
Why?
|
Reproducibility of Results | 10 | 2018 | 19862 | 0.100 |
Why?
|
Enalapril | 1 | 1993 | 327 | 0.100 |
Why?
|
Occupational Diseases | 1 | 2019 | 1472 | 0.090 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 453 | 0.090 |
Why?
|
Factor Analysis, Statistical | 2 | 2012 | 975 | 0.090 |
Why?
|
Work Capacity Evaluation | 2 | 2006 | 46 | 0.090 |
Why?
|
Health Status | 4 | 2004 | 4030 | 0.090 |
Why?
|
Health Status Indicators | 3 | 2001 | 968 | 0.090 |
Why?
|
Hospital Costs | 1 | 2016 | 980 | 0.090 |
Why?
|
State Government | 1 | 2012 | 369 | 0.090 |
Why?
|
Treatment Outcome | 12 | 2020 | 62966 | 0.090 |
Why?
|
Hearing Loss, Noise-Induced | 1 | 2010 | 144 | 0.080 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15530 | 0.080 |
Why?
|
Technology, High-Cost | 1 | 1988 | 32 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2014 | 685 | 0.080 |
Why?
|
Cost of Illness | 1 | 1998 | 1852 | 0.080 |
Why?
|
Logistic Models | 3 | 2017 | 13403 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2017 | 1357 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2008 | 1847 | 0.080 |
Why?
|
Attitude to Health | 3 | 2004 | 2051 | 0.080 |
Why?
|
Lymphoma, AIDS-Related | 2 | 1999 | 84 | 0.080 |
Why?
|
Noise | 1 | 2010 | 279 | 0.080 |
Why?
|
Clinical Trials as Topic | 11 | 1999 | 7901 | 0.080 |
Why?
|
Internet | 1 | 2020 | 3062 | 0.080 |
Why?
|
Technology, Radiologic | 1 | 1988 | 163 | 0.080 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2010 | 334 | 0.080 |
Why?
|
Antirheumatic Agents | 2 | 2008 | 1335 | 0.080 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2012 | 457 | 0.080 |
Why?
|
Taste | 2 | 1986 | 175 | 0.080 |
Why?
|
General Surgery | 1 | 2019 | 1633 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3770 | 0.080 |
Why?
|
Incidence | 5 | 2019 | 20928 | 0.070 |
Why?
|
Acute Disease | 1 | 2017 | 7141 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2007 | 4929 | 0.070 |
Why?
|
Football | 1 | 2012 | 460 | 0.070 |
Why?
|
Cross-Over Studies | 1 | 2012 | 2030 | 0.070 |
Why?
|
Government Agencies | 1 | 2007 | 156 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2283 | 0.070 |
Why?
|
Depression | 2 | 2018 | 7733 | 0.070 |
Why?
|
Self-Assessment | 2 | 1998 | 390 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2018 | 1914 | 0.070 |
Why?
|
Patient Preference | 1 | 2013 | 886 | 0.070 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2006 | 28 | 0.070 |
Why?
|
Length of Stay | 2 | 2016 | 6294 | 0.070 |
Why?
|
Inservice Training | 1 | 2009 | 392 | 0.070 |
Why?
|
Carcinoma, Basal Cell | 1 | 2011 | 545 | 0.070 |
Why?
|
Depressive Disorder | 1 | 1999 | 3748 | 0.070 |
Why?
|
Causality | 1 | 2012 | 1265 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2002 | 11472 | 0.070 |
Why?
|
Achievement | 1 | 2007 | 291 | 0.070 |
Why?
|
Health Care Costs | 1 | 2019 | 3203 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39004 | 0.070 |
Why?
|
Herpes Zoster | 1 | 2007 | 264 | 0.060 |
Why?
|
Viral Load | 2 | 2012 | 3292 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2005 | 1712 | 0.060 |
Why?
|
Cognition | 2 | 2021 | 6722 | 0.060 |
Why?
|
Prognosis | 5 | 2018 | 29010 | 0.060 |
Why?
|
Streptococcus mutans | 1 | 1984 | 100 | 0.060 |
Why?
|
Nutritional Status | 1 | 1993 | 1606 | 0.060 |
Why?
|
Occupations | 1 | 2007 | 517 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2062 | 0.060 |
Why?
|
Task Performance and Analysis | 1 | 2009 | 780 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 902 | 0.060 |
Why?
|
Self Efficacy | 2 | 2007 | 610 | 0.060 |
Why?
|
Data Collection | 4 | 2016 | 3339 | 0.060 |
Why?
|
Research Support as Topic | 1 | 1988 | 704 | 0.060 |
Why?
|
Fluorescein Angiography | 2 | 1985 | 936 | 0.060 |
Why?
|
Administration, Inhalation | 1 | 2007 | 1104 | 0.060 |
Why?
|
Sexual Behavior | 4 | 2018 | 2050 | 0.060 |
Why?
|
Drug Therapy, Combination | 5 | 2020 | 6483 | 0.060 |
Why?
|
Enterobacteriaceae | 1 | 1985 | 169 | 0.060 |
Why?
|
Medical Illustration | 1 | 2004 | 133 | 0.060 |
Why?
|
Nurses | 1 | 2013 | 2459 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9846 | 0.060 |
Why?
|
Regression Analysis | 4 | 2018 | 6452 | 0.060 |
Why?
|
Evaluation Studies as Topic | 2 | 2009 | 1676 | 0.060 |
Why?
|
Survival Analysis | 6 | 2002 | 10248 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2017 | 5310 | 0.060 |
Why?
|
Commerce | 1 | 1988 | 591 | 0.060 |
Why?
|
Information Systems | 1 | 1985 | 410 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10372 | 0.050 |
Why?
|
Hybrid Cells | 1 | 1983 | 441 | 0.050 |
Why?
|
Qualitative Research | 1 | 2011 | 2680 | 0.050 |
Why?
|
Computers | 1 | 1985 | 611 | 0.050 |
Why?
|
Culture Media | 1 | 1984 | 902 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 1988 | 820 | 0.050 |
Why?
|
Poisson Distribution | 1 | 2003 | 512 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 2 | 2008 | 3695 | 0.050 |
Why?
|
Erythropoietin | 1 | 2006 | 724 | 0.050 |
Why?
|
Bilirubin | 1 | 2003 | 424 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2018 | 7645 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3276 | 0.050 |
Why?
|
Pediatrics | 1 | 2016 | 3462 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2015 | 3861 | 0.050 |
Why?
|
Coronary Disease | 3 | 2003 | 6078 | 0.050 |
Why?
|
Mallory-Weiss Syndrome | 1 | 1981 | 2 | 0.050 |
Why?
|
Body Weight | 1 | 2012 | 4664 | 0.050 |
Why?
|
Population Surveillance | 1 | 2012 | 2616 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2018 | 57683 | 0.050 |
Why?
|
Etoposide | 1 | 2002 | 637 | 0.050 |
Why?
|
Computer Simulation | 1 | 2014 | 6191 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 1999 | 1379 | 0.050 |
Why?
|
Influenza, Human | 1 | 2012 | 1472 | 0.050 |
Why?
|
Inpatients | 1 | 2012 | 2495 | 0.050 |
Why?
|
HIV | 2 | 2005 | 1600 | 0.050 |
Why?
|
Urination Disorders | 1 | 2002 | 241 | 0.050 |
Why?
|
Meiosis | 1 | 1983 | 338 | 0.050 |
Why?
|
Technology | 1 | 2023 | 303 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2003 | 12242 | 0.050 |
Why?
|
Albuminuria | 1 | 1984 | 683 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2003 | 416 | 0.040 |
Why?
|
Eating | 1 | 2007 | 1535 | 0.040 |
Why?
|
Cohort Studies | 6 | 2011 | 40450 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 12695 | 0.040 |
Why?
|
Peripheral Vascular Diseases | 1 | 2003 | 550 | 0.040 |
Why?
|
Toilet Facilities | 1 | 2019 | 26 | 0.040 |
Why?
|
Zinc | 1 | 1983 | 683 | 0.040 |
Why?
|
Fecal Incontinence | 1 | 2002 | 240 | 0.040 |
Why?
|
Neutropenia | 2 | 2002 | 891 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2002 | 1146 | 0.040 |
Why?
|
Time Factors | 10 | 2019 | 40054 | 0.040 |
Why?
|
Adamantane | 1 | 2020 | 174 | 0.040 |
Why?
|
Calibration | 2 | 1998 | 815 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1872 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2003 | 1092 | 0.040 |
Why?
|
Cross Infection | 1 | 2008 | 1413 | 0.040 |
Why?
|
Quality Assurance, Health Care | 2 | 1999 | 2211 | 0.040 |
Why?
|
Program Evaluation | 1 | 2007 | 2485 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 623 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 1993 | 965 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2003 | 3239 | 0.040 |
Why?
|
Dipeptides | 1 | 2020 | 409 | 0.040 |
Why?
|
Infant, Premature | 2 | 2004 | 2041 | 0.040 |
Why?
|
Methyldopa | 2 | 1987 | 20 | 0.040 |
Why?
|
Spain | 1 | 1998 | 465 | 0.040 |
Why?
|
Pseudomonas aeruginosa | 1 | 1985 | 1210 | 0.040 |
Why?
|
Anemia | 1 | 2006 | 1499 | 0.040 |
Why?
|
Birth Weight | 2 | 2004 | 2068 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 1987 | 2575 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2008 | 10943 | 0.040 |
Why?
|
Heart Arrest | 1 | 2006 | 1469 | 0.040 |
Why?
|
Gastric Juice | 1 | 1976 | 64 | 0.030 |
Why?
|
Glucosides | 1 | 2020 | 446 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2002 | 970 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2003 | 1048 | 0.030 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15108 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 4029 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1999 | 654 | 0.030 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 1999 | 503 | 0.030 |
Why?
|
Administration, Oral | 3 | 2005 | 3913 | 0.030 |
Why?
|
Propranolol | 2 | 1987 | 502 | 0.030 |
Why?
|
Multiple Sclerosis | 3 | 1986 | 3076 | 0.030 |
Why?
|
Habituation, Psychophysiologic | 1 | 1976 | 154 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 1997 | 14720 | 0.030 |
Why?
|
Drug Delivery Systems | 2 | 1998 | 2217 | 0.030 |
Why?
|
Nadolol | 1 | 1994 | 30 | 0.030 |
Why?
|
Placebos | 1 | 1999 | 1677 | 0.030 |
Why?
|
Software | 2 | 1986 | 4434 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2000 | 5385 | 0.030 |
Why?
|
Diuretics | 2 | 1987 | 591 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 21596 | 0.030 |
Why?
|
Focus Groups | 1 | 1999 | 1320 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 13853 | 0.030 |
Why?
|
Critical Care | 1 | 2006 | 2640 | 0.030 |
Why?
|
Patients | 1 | 2000 | 892 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 840 | 0.030 |
Why?
|
Employment | 1 | 2000 | 1124 | 0.030 |
Why?
|
Homosexuality | 1 | 2014 | 264 | 0.030 |
Why?
|
Models, Biological | 3 | 2017 | 9581 | 0.030 |
Why?
|
Bone Density | 2 | 1997 | 3469 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1981 | 1130 | 0.030 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2016 | 436 | 0.030 |
Why?
|
Decision Making, Organizational | 1 | 1994 | 139 | 0.030 |
Why?
|
Melanoma | 1 | 2011 | 5462 | 0.030 |
Why?
|
Massachusetts | 2 | 2020 | 8662 | 0.030 |
Why?
|
Data Interpretation, Statistical | 2 | 1994 | 2714 | 0.030 |
Why?
|
Self Concept | 1 | 1999 | 1025 | 0.030 |
Why?
|
Haiti | 1 | 2014 | 551 | 0.030 |
Why?
|
Value of Life | 1 | 1992 | 97 | 0.030 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1995 | 386 | 0.030 |
Why?
|
Uremia | 1 | 1993 | 200 | 0.030 |
Why?
|
Social Behavior | 1 | 1999 | 1128 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2011 | 5662 | 0.030 |
Why?
|
Models, Econometric | 1 | 1992 | 219 | 0.030 |
Why?
|
Heptanoic Acids | 1 | 2013 | 343 | 0.030 |
Why?
|
Research Design | 2 | 2000 | 5979 | 0.020 |
Why?
|
Renal Artery | 1 | 2013 | 398 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1999 | 1548 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2235 | 0.020 |
Why?
|
Specialization | 1 | 1996 | 777 | 0.020 |
Why?
|
Physical Exertion | 1 | 1994 | 695 | 0.020 |
Why?
|
Patient Selection | 1 | 2003 | 4214 | 0.020 |
Why?
|
Texas | 1 | 2011 | 392 | 0.020 |
Why?
|
Animals | 4 | 2019 | 168561 | 0.020 |
Why?
|
Affective Symptoms | 1 | 1993 | 407 | 0.020 |
Why?
|
Models, Organizational | 1 | 1994 | 574 | 0.020 |
Why?
|
Mental Health | 2 | 1999 | 2997 | 0.020 |
Why?
|
Carcinoma | 1 | 2002 | 2374 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1994 | 1583 | 0.020 |
Why?
|
Biopsy | 1 | 2002 | 6756 | 0.020 |
Why?
|
Hydrochlorothiazide | 2 | 1987 | 98 | 0.020 |
Why?
|
Fatigue | 2 | 2006 | 1526 | 0.020 |
Why?
|
HIV-1 | 1 | 2007 | 6934 | 0.020 |
Why?
|
Life Style | 2 | 2019 | 3824 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 1999 | 2414 | 0.020 |
Why?
|
Angioplasty, Balloon | 1 | 2013 | 653 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 1995 | 1726 | 0.020 |
Why?
|
Maine | 1 | 2009 | 139 | 0.020 |
Why?
|
Women's Health | 1 | 2018 | 2034 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2002 | 11039 | 0.020 |
Why?
|
Policy Making | 1 | 1992 | 554 | 0.020 |
Why?
|
Drug Combinations | 1 | 2013 | 1961 | 0.020 |
Why?
|
Vaginitis | 1 | 1988 | 46 | 0.020 |
Why?
|
Osteoporosis | 1 | 1997 | 1581 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2948 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1980 | 2542 | 0.020 |
Why?
|
Insulin-Secreting Cells | 1 | 2015 | 891 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2615 | 0.020 |
Why?
|
Prostatitis | 1 | 1988 | 102 | 0.020 |
Why?
|
Nurse-Patient Relations | 1 | 2008 | 101 | 0.020 |
Why?
|
Medicine | 1 | 1996 | 941 | 0.020 |
Why?
|
Pyrroles | 1 | 2013 | 1143 | 0.020 |
Why?
|
Bleomycin | 2 | 1998 | 499 | 0.020 |
Why?
|
Epoetin Alfa | 1 | 2006 | 83 | 0.020 |
Why?
|
Decision Support Techniques | 2 | 1997 | 1952 | 0.020 |
Why?
|
Prevalence | 2 | 2010 | 15194 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1368 | 0.020 |
Why?
|
Blood Pressure | 4 | 1993 | 8541 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2013 | 979 | 0.020 |
Why?
|
Saquinavir | 1 | 2005 | 28 | 0.020 |
Why?
|
Risk | 3 | 2008 | 9679 | 0.020 |
Why?
|
Vincristine | 2 | 1998 | 1036 | 0.020 |
Why?
|
Age Factors | 4 | 2006 | 18355 | 0.020 |
Why?
|
Prospective Studies | 5 | 2018 | 53187 | 0.020 |
Why?
|
Statistics as Topic | 1 | 1992 | 2372 | 0.020 |
Why?
|
Classification | 1 | 1986 | 129 | 0.020 |
Why?
|
Fractures, Bone | 1 | 1997 | 1945 | 0.020 |
Why?
|
RNA, Viral | 2 | 2005 | 2899 | 0.020 |
Why?
|
Stress, Physiological | 1 | 1993 | 1402 | 0.020 |
Why?
|
Capsules | 1 | 2005 | 199 | 0.020 |
Why?
|
Coronary Vessels | 1 | 2016 | 3099 | 0.020 |
Why?
|
Individuality | 1 | 1987 | 303 | 0.020 |
Why?
|
Bacitracin | 1 | 1984 | 25 | 0.020 |
Why?
|
Tellurium | 1 | 1984 | 23 | 0.020 |
Why?
|
Agar | 1 | 1984 | 56 | 0.020 |
Why?
|
Boston | 1 | 2018 | 9305 | 0.020 |
Why?
|
Retinal Artery | 1 | 1985 | 111 | 0.020 |
Why?
|
Sucrose | 1 | 1984 | 164 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3300 | 0.010 |
Why?
|
alpha-Macroglobulins | 1 | 1983 | 64 | 0.010 |
Why?
|
Body Composition | 1 | 1993 | 2400 | 0.010 |
Why?
|
Central Nervous System | 1 | 1991 | 1354 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2006 | 13655 | 0.010 |
Why?
|
Work Schedule Tolerance | 1 | 1987 | 565 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3667 | 0.010 |
Why?
|
Myocardial Ischemia | 1 | 1994 | 2145 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1985 | 962 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6534 | 0.010 |
Why?
|
HIV Core Protein p24 | 1 | 2002 | 256 | 0.010 |
Why?
|
Rheumatology | 2 | 1985 | 576 | 0.010 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 1985 | 2099 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 1994 | 2623 | 0.010 |
Why?
|
Aneurysm | 1 | 1985 | 339 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8328 | 0.010 |
Why?
|
Cyclophosphamide | 2 | 1998 | 2236 | 0.010 |
Why?
|
Medication Adherence | 1 | 2013 | 2055 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9144 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2003 | 11690 | 0.010 |
Why?
|
Urinary Tract Infections | 1 | 1988 | 786 | 0.010 |
Why?
|
Tooth | 1 | 1983 | 207 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8621 | 0.010 |
Why?
|
Doxorubicin | 2 | 1998 | 2215 | 0.010 |
Why?
|
Health Surveys | 1 | 2011 | 4030 | 0.010 |
Why?
|
Methotrexate | 2 | 1998 | 1720 | 0.010 |
Why?
|
Hematemesis | 1 | 1981 | 23 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1994 | 4379 | 0.010 |
Why?
|
Asphyxia Neonatorum | 1 | 1982 | 107 | 0.010 |
Why?
|
Karyotyping | 1 | 1983 | 1243 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2007 | 1780 | 0.010 |
Why?
|
Dexamethasone | 2 | 1998 | 1949 | 0.010 |
Why?
|
Hemoglobins | 1 | 2006 | 1532 | 0.010 |
Why?
|
Serum Albumin | 1 | 1983 | 674 | 0.010 |
Why?
|
Stroke | 1 | 2003 | 9963 | 0.010 |
Why?
|
Self Care | 1 | 2005 | 786 | 0.010 |
Why?
|
Weight Gain | 1 | 2010 | 2282 | 0.010 |
Why?
|
Sigmoid Neoplasms | 1 | 1980 | 49 | 0.010 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2006 | 979 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2008 | 21719 | 0.010 |
Why?
|
Foscarnet | 1 | 1999 | 38 | 0.010 |
Why?
|
Creatinine | 1 | 1985 | 1916 | 0.010 |
Why?
|
Lens, Crystalline | 1 | 1982 | 388 | 0.010 |
Why?
|
Indinavir | 1 | 1999 | 74 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2013 | 2195 | 0.010 |
Why?
|
Cytomegalovirus Retinitis | 1 | 1999 | 58 | 0.010 |
Why?
|
Connecticut | 1 | 1980 | 363 | 0.010 |
Why?
|
Periodontal Diseases | 1 | 1983 | 449 | 0.010 |
Why?
|
Leadership | 1 | 2009 | 1357 | 0.010 |
Why?
|
Gastroscopy | 1 | 1981 | 206 | 0.010 |
Why?
|
Heart Failure | 1 | 2003 | 10856 | 0.010 |
Why?
|
Ganciclovir | 1 | 1999 | 259 | 0.010 |
Why?
|
Blood Proteins | 1 | 1983 | 1122 | 0.010 |
Why?
|
Exudates and Transudates | 1 | 1988 | 171 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 1996 | 5304 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1994 | 13921 | 0.010 |
Why?
|
Vomiting | 1 | 1981 | 632 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2008 | 2275 | 0.010 |
Why?
|
Triglycerides | 1 | 1985 | 2450 | 0.010 |
Why?
|
Leucovorin | 1 | 1998 | 624 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1985 | 1983 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6608 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 1985 | 2186 | 0.010 |
Why?
|
Secretory Rate | 1 | 1976 | 82 | 0.010 |
Why?
|
Gastric Acidity Determination | 1 | 1976 | 62 | 0.010 |
Why?
|
Cholesterol | 1 | 1985 | 2895 | 0.010 |
Why?
|
Electroshock | 1 | 1976 | 122 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1997 | 637 | 0.010 |
Why?
|
Punishment | 1 | 1976 | 98 | 0.010 |
Why?
|
Pilot Projects | 1 | 1988 | 8297 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1986 | 2145 | 0.010 |
Why?
|
Physicians | 1 | 1993 | 4554 | 0.010 |
Why?
|
Avoidance Learning | 1 | 1976 | 233 | 0.010 |
Why?
|
Social Support | 1 | 2004 | 2117 | 0.010 |
Why?
|
Conditioning, Operant | 1 | 1976 | 313 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1981 | 1296 | 0.010 |
Why?
|
Erythrocytes | 1 | 1983 | 2452 | 0.010 |
Why?
|
Brachytherapy | 1 | 2001 | 1246 | 0.010 |
Why?
|
Femur Neck | 1 | 1995 | 309 | 0.010 |
Why?
|
Retina | 1 | 1984 | 2611 | 0.010 |
Why?
|
Gestational Age | 1 | 1982 | 3490 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 1999 | 1402 | 0.010 |
Why?
|
Retinal Vessels | 1 | 1988 | 769 | 0.010 |
Why?
|
Prostatectomy | 1 | 2001 | 1871 | 0.010 |
Why?
|
Parents | 1 | 2006 | 3387 | 0.010 |
Why?
|
Glucose | 1 | 1984 | 4391 | 0.010 |
Why?
|
Survival Rate | 1 | 2006 | 12773 | 0.010 |
Why?
|
Health Maintenance Organizations | 1 | 1995 | 642 | 0.010 |
Why?
|
Protein Binding | 1 | 1983 | 9387 | 0.010 |
Why?
|
Electrocardiography, Ambulatory | 1 | 1994 | 585 | 0.010 |
Why?
|
ROC Curve | 1 | 1997 | 3528 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1995 | 2970 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1997 | 1171 | 0.010 |
Why?
|
Observer Variation | 1 | 1995 | 2593 | 0.010 |
Why?
|
Femur | 1 | 1995 | 1297 | 0.010 |
Why?
|
Postmenopause | 1 | 1997 | 2461 | 0.010 |
Why?
|
Cell Line | 1 | 1983 | 15994 | 0.000 |
Why?
|
Ureaplasma | 1 | 1988 | 59 | 0.000 |
Why?
|
Decision Making | 1 | 2002 | 3869 | 0.000 |
Why?
|
Mycoplasma Infections | 1 | 1988 | 118 | 0.000 |
Why?
|
Mycoplasma | 1 | 1988 | 139 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1985 | 9274 | 0.000 |
Why?
|
Phantoms, Imaging | 1 | 1995 | 2466 | 0.000 |
Why?
|
Antiviral Agents | 1 | 1999 | 2978 | 0.000 |
Why?
|
Mice | 2 | 1985 | 81045 | 0.000 |
Why?
|
Electroencephalography | 1 | 1982 | 6142 | 0.000 |
Why?
|
Rural Health | 1 | 1988 | 305 | 0.000 |
Why?
|
Chlamydia trachomatis | 1 | 1988 | 245 | 0.000 |
Why?
|
Lumbar Vertebrae | 1 | 1995 | 1844 | 0.000 |
Why?
|
Sex Factors | 1 | 1980 | 10392 | 0.000 |
Why?
|
Taste Threshold | 1 | 1984 | 11 | 0.000 |
Why?
|
Raynaud Disease | 1 | 1985 | 67 | 0.000 |
Why?
|
Family Practice | 1 | 1988 | 516 | 0.000 |
Why?
|
Multiple Myeloma | 1 | 1983 | 5169 | 0.000 |
Why?
|
Patient Dropouts | 1 | 1987 | 421 | 0.000 |
Why?
|
Chlamydia Infections | 1 | 1988 | 364 | 0.000 |
Why?
|
Clinical Competence | 1 | 1999 | 4681 | 0.000 |
Why?
|
Psychophysics | 1 | 1984 | 309 | 0.000 |
Why?
|
Methods | 1 | 1984 | 1128 | 0.000 |
Why?
|
Oral Hygiene Index | 1 | 1983 | 9 | 0.000 |
Why?
|
Dental Plaque Index | 1 | 1983 | 94 | 0.000 |
Why?
|
Periodontal Index | 1 | 1983 | 146 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1997 | 11001 | 0.000 |
Why?
|
False Positive Reactions | 1 | 1985 | 981 | 0.000 |
Why?
|
Heart Rate | 1 | 1994 | 4091 | 0.000 |
Why?
|
Scleroderma, Systemic | 1 | 1985 | 313 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1985 | 1799 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 1997 | 15056 | 0.000 |
Why?
|
Models, Statistical | 1 | 1995 | 5100 | 0.000 |
Why?
|
Rats | 1 | 1976 | 24265 | 0.000 |
Why?
|
Neurologic Examination | 1 | 1982 | 931 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1995 | 9941 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1985 | 20774 | 0.000 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1985 | 947 | 0.000 |
Why?
|
Evoked Potentials | 1 | 1982 | 1057 | 0.000 |
Why?
|
Societies, Medical | 1 | 1984 | 3740 | 0.000 |
Why?
|
Child Development | 1 | 1982 | 2222 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1985 | 12958 | 0.000 |
Why?
|
Seizures | 1 | 1982 | 2851 | 0.000 |
Why?
|
Phenotype | 1 | 1985 | 16331 | 0.000 |
Why?
|